108 Biocapital Growth Fund, LP

The fund targets growth-stage investments at Series C and later rounds, with check sizes typically ranging from $5-15 million per position. It focuses on companies with phase 2 or later clinical data.

The fund invests across multiple therapeutic areas including oncology, neurology, and rare diseases. It backs companies developing small molecules, biologics, and cell/gene therapies.

The fund sources deals through relationships with research institutions, licensing partners, and co-investment relationships with larger life sciences venture firms. Public disclosures are limited.

The fund typically participates as a minority co-investor in rounds led by larger life sciences venture capital firms. It does not generally serve as lead investor.

The fund concentrates on North America, primarily the United States. Its portfolio companies are largely located in major biotech hubs including the San Francisco Bay Area, Boston, and San Diego.